Concepedia
Statistics
Publications
30
Citations
1.6K
H-Index
21
Active since
1990
Affiliations
Daiichi-Sankyo (Japan)(Current)
The University of Tokyo
Cleveland Clinic
Fukuoka University
Daiichi Sankyo (Germany)
Hiroyuki Hanzawa is an author at Daiichi-Sankyo (Japan) specializing in medicine, natural sciences, and biochemistry.
Top concepts
MedicineNatural SciencesBiochemistryPharmacologyMolecular BiologyDrug DiscoverySignal TransductionCell BiologyMicrobiologyCell Signaling
Publications per year
1990–2023
Identification of a ubiquitin-protein ligase subunit within the CCR4-NOT transcription repressor complex
Thomas Albert, Hiroyuki Hanzawa, Yvonne I.A. Legtenberg et al. · The EMBO Journal · 2002 · 215 citations · Full text
Transcriptional Regulation, Natural Sciences, Genetics +8
Phomactin A; a novel PAF antagonist from a marine fungus Phoma sp
Michihiro Sugano, Aiya Sato, Yasuteru Iijima et al. · Journal of the American Chemical Society · 1991 · 159 citations
Biology, Fungal Diversity, Industrial Mycology +11
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Ryohei Katayama, Bo Gong, Noriko Togashi et al. · Nature Communications · 2019 · 135 citations · Full text
Molecular Mechanism Underlying Inverse Agonist of Angiotensin II Type 1 Receptor
Shin-ichiro Miura, Masahiro Fujino, Hiroyuki Hanzawa et al. · Journal of Biological Chemistry · 2006 · 125 citations · Full text
Inverse Agonist Activity, Receptor Antagonist, Pharmacotherapy +18
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw et al. · Clinical Cancer Research · 2020 · 103 citations · Full text
1–5 of 30